Hideyuki Terao

Bio: Hideyuki Terao is an academic researcher from Yokohama City University. The author has contributed to research in topics: Ureteroscopy & Nephrostomy. The author has an hindex of 14, co-authored 56 publications receiving 769 citations. Previous affiliations of Hideyuki Terao include Fujisawa City Hospital & Yokohama City University Medical Center.

Ureteral stent encrustation, incrustation, and coloring: morbidity related to indwelling times.

Abstract: Background and Purpose: Ureteral stents are a fundamental part of many urologic procedures. Serious complications, including migration, fragmentation, and stone formation, still occur, especially when stents have been forgotten for a long time. No widespread consensus for the type or indwelling time to avoid ureteral stent complications has been reached, however. We investigated the correlation between the indwelling time and encrustation, incrustation, coloration, and resistance to removal. Patients and Methods: A total of 330 ureteral stents in 181 patients were examined. Results: Overall, 155 (47.0%) stents were encrusted, and the encrustation rate was 26.8% at less than 6 weeks, 56.9% at 6 to 12 weeks, and 75.9% at more than 12 weeks. A total of 46 (13.9%) stents resisted removal, and 3 of these could not be removed by cystoscopy. The median indwelling time was 72 (14–124) days for stents that resisted removal and 31 (30–60) days for irremovable stents. The frequency of encrustation with colo...

The potential of FDG-PET/CT for detecting prostate cancer in patients with an elevated serum PSA level.

Abstract: The aim of this study is to evaluate the potential and limitation of FDG-PET/CT for detecting prostate cancer in subjects with an elevated serum prostate-specific antigen (PSA) level. Although [18F]-2-fluoro-2-deoxyglucose positron emission tomography (FDG-PET) has limited value in detecting prostate cancer, the potential of PET/CT has not been precisely evaluated, since positron emission tomography/computed tomography (PET/CT) provides accurate localization of functional findings obtained by PET. Subjects with an increasing PSA level suggestive of prostate cancer were enrolled in this study. FDG-PET/CT was performed prior to prostate biopsy and the findings were compared with the pathological results. Fifty subjects with an elevated serum PSA level took part in this study. The sensitivity, specificity and positive predictive value (PPV) of FDG-PET/CT in the prostate were 51.9% (27/52 areas), 75.7% (112/148 areas) and 42.9% (27/63 areas), respectively; those in the peripheral zone were 73.3% (22/30 areas), 64.3% (45/70 areas) and 46.8% (22/47 areas), respectively; and those in the central gland were 22.7% (5/22 areas), 85.9% (67/78 areas) and 31.3% (5/16 areas), respectively. The estimated cut-off values according to the highest odds ratio (OR) were age of 70 years [OR: 7.00, 95% confidence interval (CI): 1.89–25.93] and a PSA value of 12.0 ng/ml (OR: 10.77, 95% CI: 2.78–41.74). The FDG-PET/CT could potentially detect cancer with 80.0% sensitivity and 87.0% PPV in cases with a Gleason score of 7 or greater. FDG-PET/CT was appropriate for detecting peripheral zone prostate cancer in patients at more than an intermediate risk.

Predictive Value of Attenuation Coefficients Measured as Hounsfield Units on Noncontrast Computed Tomography During Flexible Ureteroscopy with Holmium Laser Lithotripsy: A Single-Center Experience

Abstract: Purpose: To assess the utility of attenuation coefficients as predictors of surgical outcome after a single flexible ureteroscopy (URS) with holmium laser lithotripsy. Many reports indicate that the efficacy of extracorporeal shockwave lithotripsy (SWL) can be predicted by the target's radiofrequency attenuation, measured as Hounsfield units (HUs) on noncontrast CT (NCCT). Studies of flexible URS, however, have not assessed the predictive value of attenuation coefficients on NCCT. Patients and Methods: Patients with renal stones who were treated by flexible URS with holmium laser lithotripsy between December 2009 and October 2011 at a single institute were retrospectively evaluated. Stone-free (SF) status was determined by kidneys-ureters-bladder (KUB) radiography at postoperative month 3. Correlations of possible predictors with SF status were analyzed using a logistic regression model. The comparison between groups with low and high HUs was examined using the Mann-Whitney U test. Results: There...

Ureteroscopy assisted retrograde nephrostomy: a new technique for percutaneous nephrolithotomy (PCNL).

Abstract: UNLABELLED Study Type - Therapy (case series). Level of Evidence 4. What's known on the subject? and What does the study add? Retrograde nephrostomy was first developed by Lawson et al. in 1983, and Hunter et al. reported 30 cases of retrograde nephrostomy in 1987. This procedure uses less radiation exposure and has a shorter duration compared with the previous percutaneous nephrostomy techniques. Retrograde nephrostomy using Lawson's procedure was reported in the late 1980s by several authors. But since then, few studies have been reported about this procedure due to the development of ultrasonography assisted percutaneous nephrostomy. With the arrival and development of the flexible ureteroscope (URS) both observation and manipulation in the renal pelvis are now easily achieved. The present procedure provides less radiation exposure, less bleeding, and a shorter procedure than previous percutaneous nephrostomy techniques. Using this procedure, after the needle has exited through the skin, no further steps are required in preparation for dilatation. In the present study, we continuously visualised from puncture to inserting the nephron-access sheath with the URS. OBJECTIVE • To describe a technique for ureteroscopy assisted retrograde nephrostomy. PATIENTS AND METHODS • Under general and epidural anaesthesia, the patient is placed in a modified-Valdivia position. Flexible ureteroscopy is carried out, and a Lawson retrograde nephrostomy puncture wire is placed in the ureteroscope (URS). • After the needle has exited through the skin, no further steps are required in preparation for dilatation. RESULTS • After informed consent was obtained, two patients (a 43-year-old man with left renal stones and a 57-year-old woman with right renal stones) underwent this procedure. • The URS was positioned in the middle posterior calyx and punctured toward the skin. CONCLUSIONS • This procedure involves less radiation exposure and shorter surgery than the previous percutaneous nephrostomy technique. • Our technique represents another new option for percutaneous nephrolithotomy in patients with a non-dilated intrarenal collecting system.

The EFSUMB Guidelines and Recommendations on the Clinical Practice of Contrast Enhanced Ultrasound (CEUS): Update 2011 on non-hepatic applications

Abstract: Authors F. Piscaglia1, C. Nolsøe2, C. F. Dietrich3, D. O. Cosgrove4, O. H. Gilja5, M. Bachmann Nielsen6, T. Albrecht7, L. Barozzi8, M. Bertolotto9, O. Catalano10, M. Claudon11, D. A. Clevert12, J. M. Correas13, M. D’Onofrio14, F. M. Drudi15, J. Eyding16, M. Giovannini17, M. Hocke18, A. Ignee19, E. M. Jung20, A. S. Klauser21, N. Lassau22, E. Leen23, G. Mathis24, A. Saftoiu25, G. Seidel26, P. S. Sidhu27, G. ter. Haar28, D. Timmerman29, H. P. Weskott30

The Clinical Research Office of the Endourological Society Percutaneous Nephrolithotomy Global Study: indications, complications, and outcomes in 5803 patients.

Abstract: Purpose: To assess the current indications, perioperative morbidity, and stone-free outcomes for percutaneous nephrolithotomy (PCNL) worldwide. Patients and Methods: The Clinical Research Office of the Endourological Society (CROES) collected prospective data for consecutive patients who were treated with PCNL at centers around the world for 1 year. PCNL was performed according to study protocol and local clinical practice guidelines. Stone load and location were recorded, and postoperative complications were graded according to the modified Clavien grading system. Results: Between November 2007 and December 2009, 5803 patients were treated at 96 centers in Europe, Asia, North America, South America, and Australia. Staghorn calculus was present in 1466 (27.5%) patients, and 940, 956, and 2603 patients had stones in the upper, interpolar, and lower pole calices, respectively. The majority of procedures (85.5%) were uneventful. Major procedure-related complications included significant bleeding (7....

The EFSUMB guidelines and recommendations for the clinical practice of contrast-enhanced ultrasound (CEUS) in Non-Hepatic Applications: Update 2017 (Long Version)

Abstract: The updated version of the EFSUMB guidelines on the application of non-hepatic contrast-enhanced ultrasound (CEUS) deals with the use of microbubble ultrasound contrast outside the liver in the many established and emerging applications.

Metabolic Plasticity as a Determinant of Tumor Growth and Metastasis.

Abstract: Cancer cells must adapt their metabolism to meet the energetic and biosynthetic demands that accompany rapid growth of the primary tumor and colonization of distinct metastatic sites. Different stages of the metastatic cascade can also present distinct metabolic challenges to disseminating cancer cells. However, little is known regarding how changes in cellular metabolism, both within the cancer cell and the metastatic microenvironment, alter the ability of tumor cells to colonize and grow in distinct secondary sites. This review examines the concept of metabolic heterogeneity within the primary tumor, and how cancer cells are metabolically coupled with other cancer cells that comprise the tumor and cells within the tumor stroma. We examine how metabolic strategies, which are engaged by cancer cells in the primary site, change during the metastatic process. Finally, we discuss the metabolic adaptations that occur as cancer cells colonize foreign metastatic microenvironments and how cancer cells influence the metabolism of stromal cells at sites of metastasis. Through a discussion of these topics, it is clear that plasticity in tumor metabolic programs, which allows cancer cells to adapt and grow in hostile microenvironments, is emerging as an important variable that may change clinical approaches to managing metastatic disease. Cancer Res; 76(18); 5201-8. ©2016 AACR.